National Comprehensive Cancer Network® (NCCN®) Treatment Guidelines

Pralsetinib is an NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)–recommended treatment option2

lung circle icon

NCCN Guidelines® recommend pralsetinib (GAVRETO) as a Category 2A preferred first-line treatment option for RET fusion-positive metastatic NSCLC2*

*See the NCCN Guidelines for NSCLC for detailed recommendations, including other preferred options.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
NSCLC=non–small cell lung cancer; RET=rearranged during transfection.

Safety for GAVRETO
See RET+ mNSCLC safety for GAVRETO

Explore the safety results for all RET+ mNSCLC patients studied.